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Although the associations among diabetes mellitus, cognitive functioning and
arterial stiffness have been explored previously, the degree to which arterial stiffness is
responsible for the association between diabetes and cognitive function has not been
examined. The primary aim of the current investigations is to examine the extent to
which arterial stiffness mediates the association between diabetes and cognitive function,
as well as the extent to which this indirect effect is modified by age and APOE genotype.
The sample included 590 participants (age 23-94, 62% women, 12% AfricanAmerican) from the seventh wave of the Maine-Syracuse Longitudinal
Study. Individuals with history of stroke, probable dementia, and PWV error of estimate
>0.20 were excluded. Diabetes was defined as elevated glucose or treatment. Pulse wave
velocity was used to as an indirect measure of arterial stiffness. Multiple statistical
methods were used to examine the association between diabetes and cognitive function,
as well as between PWV and cognitive function. Then, path analysis was used to
examine the direct and indirect (through PWV) associations between diabetes and
cognitive function. With adjustment for demographic and CVD risk variables,

associations between diabetes and multiple measures of cognitive ability were observed
for the APOE-ε4 carriers only. PWV was related to multiple cognitive measures, and this
association was modified by age such that the lowest performance was observed in older
individuals with elevated PWV. When diabetes, PWV and cognitive function were
included together in the analysis of paths between variables, an indirect association
between diabetes and cognitive function through PWV was observed, such that diabetes
related to higher PWV, and lower cognitive function in older APOE-ε4 carriers. These
findings may have important clinical implications with regard to attenuating the
pronounced association between diabetes and cognitive function observed for persons
who carry the APOE-ε4 allele. Accelerated arterial stiffness may possibly be treated by
the same methods that are used to treat hypertension. Clinical trials are necessary to
determine if modification of levels of PWV by drugs and other treatments will lead to an
improvement in cognitive performance. Treatment specific to APOE genotype are also a
possibility.

ACKNOWLEDGEMENTS

A special thank you to Professors Merrill Elias and Michael Robbins for their
wisdom and guidance, which has had an immeasurable impact on my development as a
researcher and individual. I would like to thank Adam Davey (Temple University) for
his statistical expertise and advise throughout my graduate career, as well as for his
service on my graduate committee. Also thanks to Professors Shawn Ell, and Alan
Rosenwasser for their helpful comments and suggestions, and also for furthering my
knowledge of psychology.

iii

TABLE OF CONTENTS
ACKNOWLEDGEMENTS ............................................................................................... iii
LIST OF TABLES ............................................................................................................ vii
LIST OF FIGURES ......................................................................................................... viii
LIST OF ABBREVIATIONS ............................................................................................ ix
1. INTRODUCTION .......................................................................................................... 1
1.1. Type 2 Diabetes – Definition and Related Measures .............................................. 3
1.1.1. Subtypes of Diabetes ......................................................................................... 3
1.1.2. Prevalence and Incidence of Type 2 Diabetes................................................... 4
1.1.3. Objective Measures Utilized in the Diagnosis of Type 2 Diabetes ................... 4
1.1.4. Measures of Diabetes Available in the MSLS .................................................. 5
1.2. Arterial Stiffness – Mechanisms and Measurement Methods. ................................ 6
1.2.1. Arterial Stiffness – Mechanisms ....................................................................... 6
1.2.2. Measures of Arterial Stiffness ........................................................................... 8
1.3. Components of the Path from Diabetes to Cognitive Function............................... 9
1.3.1. Diabetes and Cognitive Function ...................................................................... 9
1.3.2. Arterial Stiffness and Cognitive Functioning .................................................. 13
1.3.3. Arterial Stiffness as a Mediator between Diabetes and Cognitive
Performance .................................................................................................... 14
1.4. Study Hypotheses in Relation to Objectives. ........................................................ 15

iv

2. METHODS....................................................................................................................18
2.1. Sample and Design ................................................................................................ 18
2.2. Procedures .......................................................................................................... 19
2.3. Cognitive Tests and Domains............................................................................. 22
2.4. Statistical Methods ............................................................................................. 25
2.4.1. Covariate Selection....................................................................................... 25
2.4.2. Regression Analyses..................................................................................... 27
2.4.3. Path Analyses ............................................................................................... 29
3. RESULTS ..................................................................................................................... 31
3.1. Demographic and health variables ........................................................................ 31
3.2. Covariate Selection................................................................................................ 31
3.4. PWV × Age Interaction ......................................................................................... 35
3.6. Mediational Analyses ............................................................................................ 47
3.7. Secondary Analyses .............................................................................................. 54
3.8. Summary of Results .............................................................................................. 58
4. DISCUSSION ............................................................................................................... 59
4.1. Summary of Most Pertinent Findings ................................................................... 59
4.2. Diabetes, APOE Genotype, and Cognitive Function ............................................ 60
4.3. PWV, Age, and Cognitive Function ...................................................................... 61
4.4. From Diabetes to PWV to Cognitive Deficit ........................................................ 64
4.5. Cognitive Domains Associated with Diabetes ...................................................... 66
4.6. Cognitive Domains Associated with PWV ........................................................... 68
4.7. Limitations of the Current Study ........................................................................... 69

v

4.8. Strengths of the Current Study ........................................................................... 70
4.9. Summary ............................................................................................................ 71
4.10. Implications for Clinical Practice ..................................................................... 71
REFERENCES ................................................................................................................. 73
BIOGRAPHY OF THE AUTHOR................................................................................... 83

vi

LIST OF TABLES
Table 2.1.

Descriptions of the cognitive tests contributing to each composite
score indexing a cognitive domain............................................................23

Table 3.1.

Demographic information and health characteristics................................32

Table 3.2.

Variables surviving backward elimination (p = 0.10) for each of
the cognitive outcome variables.................................................................34

Table 3.3.

Regression coefficients (b) and standard errors (SE) for the
diabetes × APOE interaction......................................................................34

Table 3.4.

Regression coefficients (b) and standard errors (SE) for the
PWV × age interaction...............................................................................37

Table 3.5.

Regression coefficients (b) and standard errors (SE) expressing
the association between PWV and cognitive function by age tertiles.......38

Table 3.6.

Main effects - Regression coefficients (b) and standard errors (se)
expressing the association between measures of arterial stiffness
and cognitive functioning..........................................................................45

Table 3.7.

Arterial stiffness × age interactions - Regression coefficients (b)
and standard errors (se) for the arterial stiffness × age interaction............46

Table 3.8.

Basic model component path coefficients (b) and standard errors
(se) of the direct effects of diabetes on cognitive function and
conditional indirect effects of diabetes on cognitive function
through PWV.............................................................................................50

Table 3.9.

Extended model component path coefficients (b) and standard
errors (se) of the direct effects of diabetes on cognitive function
and conditional indirect effects of diabetes on cognitive function
through PWV.............................................................................................51

Table 3.10.

Results for the no APOE-ε4 group, basic model.......................................52

Table 3.11.

Results for the APOE-ε4 group, basic model............................................53

Table 3.12.

Results for the no APOE-ε4 group, extended model.................................55

Table 3.13.

Results for the APOE-ε4 group, extended model......................................56

vii

LIST OF FIGURES
Figure 1.1.

Pulse pressure waveforms in younger and older individuals.......................7

Figure 1.2.

Adjusted means and standard errors illustrating the relationship
between diabetes and cognitive outcome variables in the MSLS..............12

Figure 1.3.

Simplified mediational model....................................................................15

Figure 2.1.

Path model used to assess the conditional (moderated by age and
APOE) indirect effect of diabetes on cognitive function through
PWV...........................................................................................................28

Figure 3.1.

Adjusted (least squares) means for cognitive outcome measures by
diabetic status and APOE group...............................................................36

Figure 3.2.

Relationship between PWV and Global Composite residuals for
individuals under 59 years of age..............................................................39

Figure 3.3.

Relationship between PWV and Global Composite residuals
for individuals 59 – 69 years of age...........................................................40

Figure 3.4.

Relationship between PWV and Global Composite residuals
for individuals over 69 years of age...........................................................41

Figure 3.5.

PWV slopes and 95% confidence intervals by age estimated using
the Johnson-Neyman technique for the Global Composite (basic
model)........................................................................................................42

Figure 3.6.

Association between PWV and the Global Composite, as modified
by age.........................................................................................................43

Figure 3.7.

Simplified path model used to assess the conditional (moderated by
age and APOE) indirect effect of diabetes on cognitive function
through PWV.............................................................................................48

Figure 3.8.

Association between the arterial stiffness composite and the
Global Composite, as modified by age......................................................57

viii

LIST OF ABBREVIATIONS
A1C

hemoglobin A1C

AIx

augmentation index

AGE

advanced glycation end-product

APOE

apolipoprotein E

aPP

aortic pulse pressure

BMI

body mass index

BP

blood pressure

CAA

cerebral amyloid angiopathy

CES-D

Center for Epidemiologic Studies – Depression scale

COWA

Controlled Oral Word Associations

CRP

C-reactive protein

CVD

cardiovascular disease

DBP

diastolic blood pressure

HDL

high density lipoprotein

LDL

low density lipoprotein

MAP

mean arterial pressure

MSLS

Maine Syracuse Longitudinal Study

PWV

pulse wave velocity

SBP

systolic blood pressure

VSOM

Visual-Spatial Organization and Memory

ix

1. INTRODUCTION

Many studies, including studies with the Maine Syracuse Longitudinal Study
(MSLS) have shown that cardiovascular risk factors have an inverse relationship with
level of cognitive function (M. F. Elias et al., 2004; M. F. Elias, Robbins, P. K. Elias, &
Streeten, 1998; M. F. Elias, Robbins, et al., 2009). That is, higher risk for cardiovascular
events is associated with lower levels of cognitive performance, accelerated decline in
cognitive performance, and increased risk of developing dementia (M. F. Elias, P. K.
Elias, Robbins, Wolf, & D’Agostino, 2001; Elias, Goodell, & Dore, 2012). One such risk
factor for cardiovascular events, diabetes mellitus (diabetes), has been shown to relate to
cognitive function, cognitive decline, and dementia (Roriz-Filho et al., 2009).
Diabetes is not only related to cognitive function, but also to other cardiovascular
risk factors. For example, individuals with diabetes have higher blood pressure (BP),
higher levels of adiposity, and higher levels of inflammatory biomarkers (Grundy,
Brewer, Cleeman, Smith, & Lenfant, 2004). The associations between diabetes and
cognitive function remain after statistical adjustment for these risk factors (M. F. Elias, P.
K. Elias, Sullivan, Wolf, & D'Agostino, 2005; Dore, M. F. Elias, Robbins, P. K. Elias, &
Nagy, 2009), suggesting that diabetes affects cognitive function independently of these
variables. However, the diabetic state may worsen the impact of other risk factors on
cognitive function (Robbins, M. F. Elias, Budge, Brennan, & P. K. Elias, 2005).
Another risk factor for cardiovascular mortality and morbidity, arterial stiffness, is
also related to cognitive function (M. F. Elias, Robbins, Budge, Abhayaratna, Dore, & P.
K. Elias, 2009), cognitive decline (Benetos, Watfa, Hanon, et al., 2012; Watson, Sutton,
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Rosano, et al., 2011) and diabetes (see Stehouwer, Henry, & Ferreira, 2008 for review).
Arteries stiffen with aging (Noon, Trischuk, Gaucher, Galante, & Scott, 2008), and this
stiffening is accelerated in diabetic individuals (Benetos et al., 2002).
Although the associations between diabetes and cognitive function, diabetes and
arterial stiffness, and arterial stiffness and cognitive functioning have been explored in
previous studies, the degree to which arterial stiffness mediates the association between
diabetes and cognitive function is unclear. Therefore, the primary aim of the current
investigations is to examine the extent to which arterial stiffness mediates the association
between diabetes and cognitive function.
In Section 1.1, we review and describe the various types of diabetes (Section
1.1.1), descriptive data related to the prevalence of type 2 diabetes (Section 1.1.2), and
measures used to define type 2 diabetes in the context of an epidemiological study
(Section 1.1.3) and discuss measures of type 2 diabetes available in the MSLS (Section
1.1.4). In Section 1.2, we explore the concept of arterial stiffness (Section 1.2.1) and
describe the measures used to assess arterial stiffness (Section 1.2.2).
Section 1.3 describes the associations among diabetes, arterial stiffness, and
cognitive function. First, the literature relating diabetes to lowered cognitive function is
reviewed (Section 1.3.1), followed by a review of the literature relating increased arterial
stiffness to lowered cognitive function (Section 1.3.2). Finally, a theoretical mediational
model is presented. In this model, the association between diabetes and lowered cognitive
function is accounted for, at least in part, by pulse wave velocity, the gold standard index
of arterial stiffness (Section 1.3.3).

2

Section 1.4 outlines hypotheses and objectives of the current study. Section 2
outlines the sample used (Section 2.1), procedures used for data collection (Section 2.2),
cognitive variables used in the MSLS (Section 2.3), and concludes with a discussion of
the data analysis methods used in the current study (Section 2.4).

1.1. Type 2 Diabetes – Definition and Related Measures
1.1.1. Subtypes of Diabetes
There are four distinct classes of diabetes mellitus: type 1 diabetes, type 2
diabetes, gestational diabetes, and other types of diabetes caused by specific genetic
defects, pancreatic disease, or drugs/chemicals (American Diabetes Association, 2012a).
Type 1 diabetes was traditionally termed “insulin-dependent diabetes mellitus” or
“juvenile-onset diabetes”, because of it usually occurs early in life, due to an autoimmune
reaction resulting in β-cell destruction and a corresponding lack of insulin production.
Treatment with insulin is thus required for survival. In contrast, type 2 diabetes, in the
past called “non-insulin-dependent diabetes mellitus” or “adult-onset diabetes” because it
usually occurs later in life, is characterized not by lack of insulin production, but insulin
resistance (decreased sensitivity of body tissues to insulin) and hyperglycemia (elevated
levels of glucose in the blood). The pathophysiology of gestational diabetes is similar to
that of type 2 diabetes (glucose intolerance), but this form of diabetes improves or
disappears following delivery. Type 2 diabetes accounts for 90-95% of all diabetes
cases, and risk factors for this class of diabetes include both modifiable (e.g. obesity,
hypertension, physical inactivity) and non-modifiable (e.g. age, race/ethnicity, and family
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history) factors (Deshpande, Harris-Hayes, & Schootman, 2008). For these reasons this
investigation focuses on type 2 diabetes.

1.1.2. Prevalence and Incidence of Type 2 Diabetes
In epidemiology, prevalence is defined as the number of cases at a specific point
in time and incidence as the number of new cases. From 1980 to 2007, the prevalence of
self-report of diagnosed diabetes in the U.S. increased from 2.5% to 5.9%. From 1980 to
1995, the prevalence of diabetes remained relatively stable at about 3%, then began to
increase from 3.3% (8.6 million) in 1996 to 5.9% (17.4 million) in 2007. This increase
does not seem to be completely due to the increasing age of the U.S. population in
general (Centers for Disease Control, 2010) even though the prevalence of diabetes
increases dramatically with advancing age (Centers for Disease Control and Prevention,
2008). As previously noted, approximately 90-95% of these cases are type 2 diabetes.
With respect to incidence, in 2007, 1.6 million individuals aged 20 years or older were
newly diagnosed with diabetes (Centers for Disease Control and Prevention, 2008).

1.1.3. Objective Measures Utilized in the Diagnosis of Type 2 Diabetes
Diabetes is typically diagnosed on the basis of plasma glucose levels.
Specifically, subjects with fasting glucose levels greater than or equal to 126 mg/dl (7.0
mmol/l) are considered to be diabetic (American Diabetes Association, 2012a). This
glycemic cut-point was established because retinopathy (microvascular pathology in the
retina) was found to be relatively absent in individuals with glucose levels below these
4

cut-points. Above these levels, prevalent retinopathy increases in a linear fashion
(American Diabetes Association, 2012a). Previous research has shown that retinopathy is
reflective of cerebrovascular abnormalities (Cooper et al., 2006). Although there are
issues with self-report data, some studies of cognition have employed self-report of
diabetes or history of diabetes from medical records (Gregg et al., 2000; Grodstein, Chen,
Wilson, & Manson, 2001). The justification for these methods has been the fact that
many patients accurately report their medical history of diagnosis. However, it is
estimated that 26% of diabetes cases go undiagnosed (Centers for Disease Control and
Prevention, 2008). Therefore objective measures are preferable and will be used to define
diabetes in the current study.
Recently, a more long-term measure of glucose levels, glycated hemoglobin
(hemoglobin A1C), has been used to assess glucose levels, and therefore risk of
retinopathy associated with diabetes (American Diabetes Association, 2012b). This index
is not directly applicable to the proposed work as the MSLS does not have data for
hemoglobin A1C. However, well established measures widely used in clinical practice
are used in the current study.

1.1.4. Measures of Diabetes Available in the MSLS
The MSLS is a 35-year longitudinal study of hypertension and related
cardiovascular risk factors as they relate to cognitive functioning (Elias, Goodell,
Robbins, in press; Elias, Robbins, et al., 2004). It consists of seven serial examinations
(waves), with each examination separated by a mean difference of 4.5 years. However,
until wave 6, the information obtained about diabetes comprised predominantly self5

report measures of diagnosis, type, and medications from waves 1 to 5. Beginning with
wave 6 and continuing though wave 7, fasting blood samples were drawn at each wave of
the study and a number of assays were performed, including plasma glucose levels.
Therefore, for the current study, which involves wave 7 data, objective data (blood
glucose level determinations) are used to ascertain diabetic versus non-diabetic status.
In the following section the concept of arterial stiffness (measured by pulse wave
velocity) is introduced and methods of measurement are discussed. The importance of
these definitions and this phenomenon in relation to the proposed work are then
explained.

1.2. Arterial Stiffness – Mechanisms and Measurement Methods.
1.2.1. Arterial Stiffness – Mechanisms
During the course of “normal” aging, the human arterial system undergoes a
process of arterial stiffening, that is, a decrease in distensibility of the large arteries (i.e.
the aorta, carotid, iliac, femoral, and brachial arteries). This process is driven by several
factors, including the reduction of arterial elastin content, an increase in collagen content,
and thickening of the arterial wall. When the left ventricle contracts during systole, a
pressure wave (or “pulse wave”) is created, and this pressure wave propagates along the
aorta to distal arterial bifurcations. The wave is then reflected back toward the heart. In
healthy younger individuals, this reflected wave is timed so that it augments diastolic
blood pressure. With the increased stiffness in older age, the pulse wave travels through
the vasculature faster, and therefore is reflected back sooner, resulting in an augmentation
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of systolic blood pressure. This phenomenon manifests itself as an increase in pulse
pressure (the difference between systolic and diastolic blood pressure) and a
corresponding higher prevalence of isolated systolic hypertension in older individuals
(Greenwald, 2007). Figure 1.1 illustrates the differences in pulse waves between younger
and older individuals.

Figure 1.1. Pulse pressure waveforms in younger (left) and older (right) individuals.

In addition to its relationship with aging, several pathological processes are
related to increased arterial stiffness. These include endothelial dysfunction,
atherosclerosis, and smooth muscle cell function. Age-related arterial stiffness is
accelerated by disorders such as diabetes and hypertension and is predictive of
cardiovascular morbidity and mortality (Wang, Keith, Struthers, Feuerstein, 2008).

7

1.2.2. Measures of Arterial Stiffness
Due to the increase in pulse pressure observed with increased arterial stiffness,
pulse pressure has been used as a measure of arterial stiffness in previous studies (P.K.
Elias, M. F.. Elias, Robbins, & Budge, 2004). However, as pulse pressure is derived
from peripheral (i.e. brachial) blood pressure measures, it may not reflect stiffness of the
central arteries (Laurent, Cockcroft, Van Bortel, et al., 2006). Aortic pulse wave velocity
(PWV), the speed of the pressure wave along the aorta, is considered the gold standard
non-invasive measure of central arterial stiffness (Laurent et al., 2006), and is reliably
assessed by applanation tonometry (see Section 2.2). Additionally, the percentage
increase of the systolic pressure attributable to the reflected wave can be determined (see
Figure 1.1) through analysis of the pulse wave; this measure is referred to as the
augmentation index (AIx). Both of these measures have been used to measure arterial
stiffness in previous studies (see review by O’Rourke & Hashimoto, 2008), and are
available at wave 7 of the MSLS.
Due to the limitations of the augmentation index (Cheng, Tang, Cheng, Huang,
Wang, 2007), this measure will only be used in secondary analyses in the current study.
As PWV is the preferred measure of arterial stiffness (Laurent et al., 2006), this measure
will be the primary predictor. The main limitation of PWV has been absence of
normative data by age, but these data are now available from two major studies,
(Reference Values for Arterial Stiffness Collaboration, 2010; M. F. Elias, Dore, et al.,
2011), including the Maine Syracuse Longitudinal Study.
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In the following section, previous research relating diabetes and arterial stiffness
to cognitive function will be reviewed. Additionally, the rationale for considering PWV
as a possible mediator between diabetes and cognitive function will be discussed.

1.3. Components of the Path from Diabetes to Cognitive Function
1.3.1. Diabetes and Cognitive Function
The relationship between diabetes and cognitive function has been investigated
extensively and a number of recent reviews are available (Biessels, Deary, & Ryan, 2008;
Kodl & Seaquist, 2008; Roriz-Filho, Sa-Roriz, Rosset, et al., 2009; van den Berg,
Reijmer, & Biessels, 2009; Wrighten, Piroli, Grillo, & Reagan, 2009). Although some
studies suggest that cognitive function is unrelated to diabetic status (e.g.
Asimakopoulou, Hampson, & Morrish, 2002), a majority of studies indicate that diabetes
is associated with lowered cognitive function (van den Berg, Kloppenborg, Kessels,
Kappelle, & Biessels, 2009). In the following section, the literature relating diabetes to
cognitive function, including relevant MSLS investigations, will be reviewed. Although
diabetes has also been related to dementia (Cukierman, Gerstein, & Williamson, 2005),
the proportion of persons with dementia in the MSLS study is very low (0.3%).
Consequently, the current study and the remainder of the discussion on diabetes and
cognitive function focus on cognitive performance in non-demented individuals.
In the following section, we describe cognitive abilities and domains associated
with diabetes. Here, the term “ability” refers to measures of performance indexed by a
single test. In contrast, the term “domain” is used to refer to performance indexed by
multiple tests (i.e. composite scores derived from factor analysis).
9

1.3.1.1. Cognitive Abilities and Domains Associated with Diabetes. An
association between diabetes and cognitive function was first described in 1922 (Miles &
Root, 1922). Diabetic individuals performed more poorly than non-diabetic comparison
groups on tests of memory, arithmetic, and psychomotor speed. Since then, there have
been at least 278 studies on the topic and a wider variety of cognitive abilities have been
measured. Although the specific cognitive tests used vary across studies, some
generalizations can be made concerning the cognitive abilities related to diabetes. The
most common finding is that diabetic subjects perform more poorly than nondiabetic
subjects on tests of attention, verbal and non-verbal memory, and processing speed (Kodl
& Seaquist, 2008; Roriz-Filho et al, 2009; van den Berg, Reijmer, & Biessels, 2009).
There is less agreement on other cognitive abilities, but some investigators have reported
that executive function (Kodl & Seaquist, 2008; Roriz-Filho et al, 2009), psychomotor
speed, and complex motor function (Kodl & Seaquist, 2008) are lowered in diabetic
individuals compared to non-diabetic individuals. A pattern of cognitive domains
consistent with the literature have been found in the MSLS.
1.3.1.2. Findings from the MSLS. In the MSLS, cognitive function is indexed by
several composite scores derived by principal components and factor analyses (M. F.
Elias et al. 2006) and thus with the exception of one cognitive outcome variable (WAIS
Similarities), assesses cognitive domains. These include Working Memory, Verbal
Memory, Visual-Spatial Memory/Organization, and Scanning and Tracking. The test
battery also includes the Similarities subtest of the Wechsler Adult Intelligence Scale. A
Global composite was constructed from each of the tests making up the composites and
the Similarities Test. Similarities is always used as a separate measure as it loaded at an

10

approximately equal level on each of the other composite scores (factors) during the
factor analytic process. These composites have been used in multiple studies and are
now incorporated into the literature and thus a new factor analysis was not done in this
investigation (Elias, M. F., Robbins, et al., 2004). The tests and the composite scores are
summarized in Section 2.3.
Figure 1.2 shows results in a recent study (Dore, Elias, Robbins, Elias, 2009) of
diabetes and cognitive performance. Diabetic study participants exhibited lower
performance (compared with non-diabetic participants) on Similarities, and all of the
Composite score measures, with the exception of the Verbal Memory composite (see
Figure 1.2), although the trend was for diabetic subjects to also perform more poorly on
this composite. These data, along with many previous findings discussed in the previous
section provide strong evidence that diabetes is associated with multiple domains of
cognitive function.
1.3.1.3. APOE Genotype as an Effect Modifier. Cardiovascular disease risk
factors other than diabetes have also been shown to relate to cognitive function. Of these
risk factors, presence of at least one apolipoprotein E (APOE) ε4 allele, is of particular
interest for the current study, as this factor has been shown to modify the association
between diabetes and cognitive function.
The presence of at least one apolipoprotein E (APOE) ε4 allele is associated with
dementia and lowered levels of cognition (Farrer, Cupples, Haines, et al., 1997; Small,
Rosnick, Fratiglioni, et al., 2004). Aside from serving as a CVD risk factor in its own
right, presence of the APOE ε4 allele has been shown to modify the effects of other CVD
risk factors (e.g., M. F. Elias et al., 2006), including diabetes, on cognitive function
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Figure 1.2. Adjusted means and standard errors illustrating the relationship between
diabetes and cognitive outcome variables in the MSLS. Means are adjusted for diabetes,
APOE group, age, education, sex, race/ethnicity, SBP, smoking, triacylglycerols, chronic
kidney disease, BMI, alcohol consumption, depressed mood, CRP, prevalent CVD, and
tHcy. All p-values for comparisons between non-diabetic and diabetic subjects are p<
.05, with the exception of Verbal Memory (p= .25). Adapted from Dore, M. F. Elias,
Robbins, & P. K. Elias (2009).
VM = Verbal Memory
WM = Working Memory
VSOM = Visual-Spatial Memory/Organization
ST = Scanning & Tracking
SIM = Similarities
MMSE = Mini-Mental State Examination
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(Haan, Shemanski, Jagust, et al., 1999; Dore, Elias, Robbins, Elias, & Nagy, 2009). A
recent study using data from the MSLS found that diabetic APOE ε4 carriers exhibited
lower levels of cognitive performance, although non-diabetic APOE ε4 carriers and noncarriers did not differ in terms of performance on cognitive measures. That is, lowered
cognitive performance was observed in diabetic subjects, and this effect was more
pronounced in those with at least one APOE ε4 allele.

1.3.2. Arterial Stiffness and Cognitive Functioning
As is true for other risk factors for CVD, higher levels of arterial stiffness have
been shown to relate to lowered levels of cognitive function (M. F. Elias, Robbins, et al.,
2009), and more accelerated cognitive decline (Laurent, Cockroft, van Bortel,et al., 2006;
Waldstein, Rice, Thayer, Najjar, Scuteri, & Zonderman, 2008; Benetos, Watfa, Hanon, et
al., 2012; Watson, Sutton, Rosano, et al., 2011) in older, but not younger individuals. A
recent study using data from wave 7 of the MSLS (M. F. Elias, Robbins, et al., 2009)
found that arterial stiffness, as indexed by PWV, interacted with age in relation to
multiple cognitive domains. The combination of older age and higher PWV was found to
be associated with the lowest level of cognitive performance. Similarly, in the Baltimore
Longitudinal Study of Aging, Waldstein, Rice, Thayer, Najjar, Scuteri, & Zonderman
(2008) found an interaction between PWV and cognitive change, such that individuals
with the highest PWV exhibited the most pronounced rates of cognitive decline.
Therefore, all statistical analyses involving arterial stiffness (described in later sections)
involved examination of interactions with age.
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1.3.3. Arterial Stiffness as a Mediator between Diabetes and Cognitive Performance
Diabetes is associated with increased cardiovascular disease, including peripheral
arterial disease, coronary heart disease, and cerebrovascular disease (Kannel & McGee,
1979). The vascular nature of the chronic complications of diabetes is not surprising,
given that the prevalence of retinal microvascular lesions forms the basis for defining
diabetes based on circulating glucose levels (American Diabetes Association, 2012a).
The association between diabetes and increased arterial stiffness is wellestablished (see Stehouwer et al., 2008 for review). Increased atherosclerotic plaque
deposition, exacerbated by the increased inflammatory (i.e. immune) response
characteristic of the diabetic state is one mechanism which leads to increased arterial
stiffness. Chronic hyperglycemia results in the accelerated formation of advanced
glycation endproducts (AGEs), promoting the formation of oxidized low density
lipoproteins (LDL; Basta, Schmidt, & De Caterina, 2004), which is more atherogenic
than normal LDL (Xu, He, & King, 2005). In addition, increased oxidative stress
(increased production of reactive oxygen species), possibly due to increased AGE
formation (Stitt, Jenkins, & Cooper, 2002) or resulting directly from chronic
hyperglycemia (Brownlee, 2001), may decrease bioavailability of nitric oxide (a
vasodilator) and activate the protein kinase C pathway, resulting in maintenance of a
chronic inflammatory state (Jenkins, Hill, & Rowley, 2008). In addition to factors
leading to increased atherosclerotic plaque deposition, diabetes is also associated with
increased arterial calcification, further increasing arterial stiffness (Chen & Moe, 2003).
Increased systemic inflammation (Teunissen et al., 2003), arterial calcification
(Rosano, Naydeck, Kuller, Longstreth, & Newman, 2005), oxidative stress (Berr,
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Richard, Roussel, & Bonithon-Kopp, 1998), and increased atheroma deposition (Romero
et al., 2009) have all been associated with decreased levels of cognitive performance,
brain infarction, and higher severity of white matter lesions. The extent to which arterial
stiffness (perpetuated by the above mechanisms) mediates the association between
diabetes and cognitive function is unclear; the primary objective of the proposed study is
to address this question. In the next section, we discuss these objectives in relation to
specific hypotheses.
b

Diabetes

Arterial Stiffness
a
c

Cognitive Function
Figure 1.3. Simplified mediational model.
1.4. Study Hypotheses in Relation to Objectives.
To our knowledge, there are no studies that have investigated the extent to which
arterial stiffness mediates the association between diabetes and cognitive function. As can
be seen in Figure 1.3, this mediational model consists of two important paths: 1) the
direct association between diabetes and cognitive function (represented by path a); and 2)
the indirect association between diabetes and cognitive function through PWV
(represented by paths b and c). Given that cognitive function is the outcome of interest,
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before analyzing a full path model, the association between diabetes and cognitive
function, and the association between PWV and cognitive function will be examined.
The following section describes the above objectives and related hypotheses in more
detail.

Objectives of the proposed work together with associated hypotheses were
as follows:

1.

To examine the association between diabetes and cognitive function at wave 7 of
the MSLS, as modified by APOE genotype.

Hypothesis: Previous associations observed at wave 6 of the MSLS (Dore et al.,
2009) will be replicated at wave 7.
Rationale. This step is necessary to establish this association for the later path
analysis aspect of the study (see hypothesis 3). Additionally, this step will be used to
establish covariates to be used in later path analyses. It is also important because
previous work with the MSLS data have used Wave 6 data.

2. To determine whether previously reported associations between arterial stiffness and
cognitive function in cross-sectional studies will be observed at wave 7 of the MSLS.

Hypothesis: Consistent with a previous MSLS study, arterial stiffness (as measured
by pulse wave velocity) will interact with age such that the lowest cognitive
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performance levels will be observed for older individuals. Most importantly, using
new methods for assessing moderated mediation (discussed in Section 2.4), we will
determine the ages at which this negative association between pulse wave velocity
and cognitive function is observed.

3. To determine, using path analysis, whether arterial stiffness mediates the association
between diabetes and cognitive functioning using cross-sectional data at wave 7.
Additionally, to examine whether age, a strong predictor of PWV, moderates the
effect of arterial stiffness as an intervening variable between diabetes and cognitive
function.

Hypothesis. Arterial stiffness (defined as PWV in primary analyses) will mediate the
association between diabetes and cognition as indicated by path analysis; specifically,
there will be an indirect effect observed for diabetes through PWV on cognitive
function. Additionally, this relationship will be modified by age and APOE genotype,
such that the association between arterial stiffness and cognitive function (and
therefore the indirect path from diabetes through PWV to cognitive function) will be
of higher magnitude for older individuals with an APOE-ε4 allele.
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2. METHODS
2.1. Sample and Design
Cross-sectional data were taken from the seventh serial repetition (wave 7) of the
Maine-Syracuse Longitudinal Study, a community-based study of CVD risk factors and
cognition begun in Syracuse, New York in 1974. Recruitment and data collection
procedures have been described in detail previously (Elias et al., 2006). The MSLS is an
open-enrollment longitudinal study in which new individuals are recruited at each wave.
Wave 7 was the first and only wave in which PWV was measured.
Of the 626 participants (24 to 93 years of age) with PWV at wave 7, participants
were excluded in the following sequence: 1) history of acute stroke (n= 14); 2) probable
dementia (n= 2); 3) PWV error of estimate >0.20 (n= 20); and missing APOE genotype
data (n= 44). The PWV error of estimate is a measure of the quality of the PWV
measurements, with lower values being a sign of higher-quality PWV assessments.
Measurements with PWV error of estimate >0.20 are not considered suitable for analysis.
The final sample consisted of 546 participants. We did not exclude persons with
diagnosed mild cognitive impairment because we wished to retain the full range of
variation in continuously distributed test scores, while eliminating persons who showed
major decrements in performance level and who were often able to complete only few, if
any, of the tests in our battery (i.e. those with dementia). Acute stroke can have
devastating effects on cognition and serves as a major confounder and thus is excluded in
many studies of CVD risk factors in relation to cognitive performance (M. F. Elias et al.,
2012; M. F. Elias et al., in press).
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History of acute stroke, defined as occurrence of a focal neurological deficit of
acute onset persisting more than 24 hours, was based on self-report and record review
indicating a diagnosis of acute stroke. The clinical diagnosis of dementia, as in the case
in the Framingham Heart Study (M. F. Elias et al., 2000) was based on MSLS expert
committee review (neuropsychologists, social psychologists, geriatric physician) of
cognitive data including the MMSE and confirmatory medical records including
significant other informant report. The National Institute of Neurological and
Communicative Diseases and Stroke/Alzheimer’s Disease and Related Disorders
Association criteria were used for this diagnosis (McKhann, Drachman, Folstein, et al.,
1984).

2.2. Procedures
Participants completed the Center for Epidemiological Studies Depression Scale
(CES-D; Radloff, 1977) within 1 week prior to reporting to the MSLS laboratory
(Syracuse, New York) for neuropsychological testing. Following a fast from midnight, a
blood sample was drawn in the morning and was followed by a light breakfast and
interview (including medical history). Subsequently, after supine rest for 15-minutes,
five reclining, five standing, and five sitting automated blood pressure (BP)
measurements (GE DINAMAP 100DPC-120XEN; GE Healthcare) were obtained
sequentially with a 5-minute interval between each set of measurements.
Neuropsychological testing followed the BP measurements. Tests were presented
in the same order for each individual because of the necessity of uniform sequencing and
standard presentation of the Wechsler Adult Intelligence Scale subtests, the Wechsler
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Memory Scale subtests, trails A and B and other measures. Brief rest periods were given
whenever participants appeared to be in need of a rest before continuing. All assay
methods used to derive data on independent variables and covariates have been described
previously (Elias et al, 2006).
Diabetes was defined by treatment with insulin, oral glucose-lowering agents, or
by fasting glucose level of 126 mg/dl (7 mmol/l) or higher. Objective data on duration of
diabetes were not available to the study, but persons with diabetes at wave 7 (objectively
defined) were asked to estimate the duration of their diabetes and this was used as a
descriptive variable, as is the case in most previous work.
Pulse wave velocity was assessed noninvasively in a supine position, using the
SphygmoCor system (AtCor Medical) with applanation tonometry (M. F. Elias, Robbins,
et al., 2009; M. F. Elias, Dore, et al., 2011). Carotid-femoral path length was measured as
the difference between the surface distances joining the suprasternal notch, the umbilicus,
and the femoral pulse, as well as the suprasternal notch and the carotid pulse. Carotidfemoral transit time was estimated in 8 to 10 sequential ECG-gated femoral and carotid
waveforms as the average time difference between the onset of the femoral and carotid
waveforms. The foot of the pulse wave was identified using the intersecting tangent
method. PWV was calculated as the carotid-femoral path length divided by the carotidfemoral transit time (O’Rourke, Pauca, & Jiang, 2001). This is a noninvasive and
reproducible method to determine arterial stiffness (Laurent, Cockcroft, Van Bortel, et
al., 2006).
Age and education are measured in years. Ethnicity includes African American,
Hispanic, Asian American, Caucasian, and American Indian. Because of the small
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number of minority participants (~15%), and the small number of non-African-American
minorities in particular (~3%), this variable is coded as African American vs. other.
Standard APOE genotyping used polymerase chain reaction and restriction
enzyme digest with HhaI (Hixson & Vernier, 1990). Serum creatinine was determined
using a two-point rate test type on a Johnson and Johnson VITROS instrument (Ortho
Clinical Diagnostics). Coefficients of variation for these procedures were less than 5.0%.
Estimated glomerular filtration rate was derived from the four-variable (serum creatinine,
age, sex and ethnicity) Modification of Diet in Renal Disease study equation (Levey AS,
Bosch JP, Lewis JB et al., 1990; Rule, Gusak, Pond, et al., 2004). Chronic renal disease
(yes/no) was defined as estimated glomerular filtration rate <60 ml min–1 (1.73 m2)–1.
Determinations of high sensitivity C-reactive protein (CRP), plasma homocysteine
(tHcy), triglycerides and glucose were performed as previously described (Elias et al.,
2006). Mean systolic BP (SBP) and diastolic BP (DBP) were determined by taking the
average of 15 BP measurements (described previously). Additional covariates used in
various analyses included: BMI (kg/m2), self-report of number of cigarettes smoked
per week, alcohol consumption (g/week), and self-reported presence of CVD confirmed
by medical records and/or treatment. As in the Framingham Heart Study (Elias et al.,
2004), CVD was defined as the presence of any one of the following: (1) myocardial
infarction (3.7%); (2) coronary artery disease (7.5%); (3) heart failure (1.4%); (4) angina
pectoris (3.6%); (5) transient ischemic attack (1.9%).
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2.3. Cognitive Tests and Domains
We employed the Similarities subtest from the Wechsler Adult Intelligence Scale,
and four composite test scores derived from a previous factor analysis of individual tests
in the MSLS battery for this study population (Elias et al., 2006). The four composite
scores were Visual–Spatial Memory and Organization (Visual Reproductions—
Immediate and Delayed, Matrix Reasoning, Block Design, Object Assembly, and the
Hooper Visual Organization Test), Scanning and Tracking (Trail-Making A and B, Digit
Symbol Substitution, and Symbol Search), Verbal Memory (Logical Memory—
Immediate and Delayed, and the Hopkins Verbal Learning Test) and Working Memory
(Digit Span Forward and Backward, Letter–Number Sequencing, and Controlled Oral
Word Associations). The Similarities subtest was used as a separate measure because it
loaded in an approximately equal manner on multiple composite scores in the previous
factor analysis. In addition to the factor analyses, reducing the number of outcome
variables, we followed a protection rule in which none of the results for individual tests
would be interpreted in the absence of a significant result for the Global composite score.
More detailed descriptions of the individual tests are given in Table 2.1.
Consistent with previous MSLS studies, scores (time in seconds) for Trails A and B were
log transformed. Then, to construct the composite scores, the individual tests related to
each composite were expressed in z scores and added (Elias et al., 2006). The composite
scores were again transformed to z scores. Composite scores were used to decrease error
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Table 2.1. Descriptions of the cognitive tests contributing to each composite score indexing a cognitive domaina.
Test Composite/
Cognitive Ability Measured
Tests Included in the Composite
Verbal Episodic Memory
Logical Memory-Immediate Recall b

Immediate memory, verbal

Logical Memory-Delayed Recall b

Delayed memory, verbal

Hopkins Verbal Learning Test

Verbal learning and memory
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Visual-Spatial Organization/Memory
Visual Reproductions-Immediate
Recall b
Visual Reproductions-Delayed Recall b

Immediate recall, visual memory, and visual-spatial problem solving
Delayed recall, visual memory and visual-spatial problem solving

Matrix Reasoning c

Abstract reasoning and pattern recognition

Block Design d

Visual-spatial perception, organization and construction

Object Assembly d

Speed of visual-spatial organization

Hooper Visual Organization

Visual-spatial organization; some demands on executive function

Scanning and Tracking
Trail Making A e

Visual scanning and tracking; concentration and attention

Trail Making B e

Trails A plus demands on executive function abilities

Digit Symbol Substitution d

Psychomotor performance

Symbol Search c

Visual processing speed

Working Memory

Table 2.1. (cont.)
Test Composite/
Tests Included in the Composite

Cognitive Ability Measured

Working Memory
Digit Span Forward d

Attention and concentration

Digit Span Backward d

Attention, concentration, and working memory

Letter-Number Sequence c

Information processing while holding information in memory

Controlled Oral Word Associations

Verbal fluency and executive functioning

Executive Function

24

Trail Making B e

Trails A plus demands on executive function abilities

Controlled Oral Word Associations

Verbal fluency and executive functioning

Similaritiesd

Verbal intelligence and abstract reasoning

a

The tests employed in each composite score/domain define the abilities measured by that domain.

b

Origin Wechsler Memory Scale-Revised

c

Origin Wechsler Adult Intelligence Scale III

d
e

Origin Wechsler Adult Intelligence Scale

Origin Halstead-Reitan Neuropsychological Test Battery

associated with analyses involving multiple related cognitive outcomes and to permit us
to examine theoretically relevant cognitive domains. These composite scores were
derived from principal components analyses and factor analyses; this procedure is
outlined in a previous study (M. F. Elias, et al., 2006).
This linear transformation results in a mean of zero and an SD of 1.00 for each
test and enables expression of regression coefficients for the cognitive measures in terms
of SD units. The previously identified composites (factors) (Elias et al., 2006) were
confirmed via replication of the factor analysis for the present sample. In addition to
composite scores, a Global composite score was calculated by averaging the z scores for
all individual tests (excluding the MMSE). The MMSE was considered to be a separate
measure of mental status.
The University of Maine Institutional Review Board approved the protocol for
this investigation. Informed consent for data collection was obtained from all
participants.
2.4. Statistical Methods
The major statistical analyses consisted of 3 phases: 1) covariate selection from
candidate covariates for use in extended models; 2) analysis of the bivariate relationships
forming the component paths using basic and extended covariate models; and 3) analysis
of the complete path model.
2.4.1. Covariate Selection
Previous empirical data, theory and statistical methods were used in conjunction
to select covariates. Beginning with a list of candidate covariates theoretically and
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empirically relevant to the associations among diabetes, arterial stiffness, and cognitive
function, final models were obtained by following 2 steps: 1) potential covariates which
did not show a relationship with diabetes, the primary predictor of interest, were dropped;
and 2) a stepwise backward elimination was performed, with a basic set of covariates
fixed in the model, and any covariates not meeting the inclusion criteria (p< .10) were
excluded from the models. These steps were followed with the goal of obtaining the most
parsimonious covariate set and to limit loss of statistical power and sensitivity in path
analysis which is associated with the use of an excessive number of covariates.
The basic covariate set, age, education, gender, race/ethnicity, height, weight,
heart rate, and mean arterial pressure (MAP) was used in all analyses. Additional
candidate covariates included additional variables which were found to differ between
diabetic and non-diabetic individuals. A candidate variable may be defined as one that is
considered for a covariate set based on a bivariate relationship with diabetes but subject
to elimination given the need to avoid multicollinearity. Where more than one method of
assessing a covariate was available, alternate measures of these covariates were included
in sensitivity analyses, i.e. secondary and tertiary analysis done to test robustness of the
statistical effect with different definitions of parameters or different models. Candidate
covariates included components of the metabolic syndrome (elevated blood pressure,
dyslipidemia, and adiposity), renal function, smoking, alcohol consumption, depressed
mood, cardiovascular disease, plasma homocysteine, heart rate, and antihypertensive
drug treatment.
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2.4.2. Regression Analyses
Following preliminary analyses and covariate selection, multiple linear regression
analyses (SAS PROC GLM) were employed to examine the cross-sectional associations
between 1) diabetes (independent variable) and cognitive function (dependent variable)
and 2) pulse wave velocity (independent variable) and cognitive function (dependent
variable). These analyses involved first using a basic covariate set (age, education,
gender, race/ethnicity, height, weight, heart rate, MAP) and then forming an extended
covariate set, adding variables surviving the covariate selection procedures outlined
above. All covariates within a covariate set were entered simultaneously with the
independent variable.
As previous research from the MSLS has shown that the relationship between
diabetes and cognitive function is modified by APOE genotype, diabetes × APOE
genotype interactions were assessed. Similarly, previous MSLS studies have shown that
age modifies the association between PWV and cognitive function, PWV × age
interactions were also examined. As the PWV × age interaction involves two continuous
variables, the nature of this interaction was probed using both classic methods (i.e.
splitting the distribution of age into tertiles), as well as a new method outline by Hayes
(2012). This method involves examining the path model outlined in Figure 2.1 and
computing predicted slopes for PWV at each value of age, using the Johnson-Neyman
technique. This method has the advantage of keeping both components of the interaction
term as continuous variables, rather than grouping them using arbitrary cutpoints.
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Figure 2.1. Path model used to assess the conditional (moderated by age and APOE) indirect effect of diabetes on cognitive function
through PWV. Hayes (2012) model 22
Conditional indirect effect of diabetes on cognition through PWV = (a1 + a3[APOE]) (b1 + b3[age] )
Conditional direct effect of diabetes on cognition = c'1 + c'3[APOE]

Further, this method also allows determination of the values of age for which there is a
significant relationship between PWV and cognitive function, without the loss of power
associated with other methods.
2.4.3. Path Analyses
Following the assessment of diabetes × APOE and PWV × age interactions in
relation to cognitive function, these interactions were combined into the more
comprehensive path model shown in Figure 2.1. It should be noted that in discussing this
model, the term “effect” is used not with the implication of a causative relationship
between predictors and outcomes, but rather to use terminology consistent with path
analysis. In this model, there are two effects of interest: 1) the direct effect of diabetes in
relation to cognitive function and 2) the indirect effect of diabetes through PWV on
cognitive function. This model also includes both the diabetes × APOE interaction and
the PWV × age interaction. As can be seen in the footnote to Figure 2.1, the direct effect
of diabetes on cognitive function is conditional on APOE genotype. Similarly, the
indirect effect of diabetes on cognitive function is conditional on both APOE and age.
Specifically, the conditional direct effect of diabetes on cognitive function is the
combination of the diabetes → cognitive function path (c′1) and the diabetes × APOE →
cognitive function path (c′3). Similarly, the conditional indirect effect is a combination of
the diabetes → PWV path (a1), the diabetes × APOE → PWV path (a3), the PWV →
cognitive function path (b1), and the PWV × age → cognitive function path (b3).
Using this model, conditional direct effects for diabetes were computed for each
APOE group, and conditional indirect effects for diabetes were computed for each APOE
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group. As conditional indirect effects involved continuous age, two methods were used
to probe these effects: 1) examination of the indirect effects at the 5th, 25th, 50th, 75th, and
95th percentiles of age, and 2) examination of indirect effects across the complete
observed range of age. All standard errors and confidence intervals were computed using
bootstrapping (5000 samples), as recommended by the author of the macro (Hayes,
2012).
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3. RESULTS
3.1. Demographic and health variables
Table 3.1 shows demographic and health variables for non-diabetic and diabetic
individuals separately. Non-diabetic and diabetic individuals differed on all variables
with the exception of age, smoking habits, DBP, mild renal dysfunction, depressed mood,
and APOE genotype. Diabetic individuals tended to have higher SBP, higher BMI and
waist circumference, higher triglycerides, lower HDL cholesterol, and were more likely
to be hypertensive. Interestingly, diabetic individuals showed lower total and LDL
cholesterol levels, most likely due to the higher proportion of diabetic participants treated
for elevated cholesterol, possibly due to an emphasis on diabetes control.

3.2. Covariate Selection
Table 3.1 shows all possible variables for consideration for backward
elimination, i.e. possible confounders. Of these, the following differed between nondiabetic and diabetic individuals: alcohol consumption, triglycerides, plasma
homocysteine, serum creatinine, CES-D score, history of CVD, treatment with
antihypertensive medications, and treatment with lipid-lowering medications. We did not
adjust for antidiabetic medications, because 91% of the diabetic individuals were treated
for diabetes at Wave 7 of the MSLS. Further, because the majority (89%) of

31

Table 3.1. Demographic information and health characteristics
Non-diabetic
Variable
(n = 462)
Age (years), M (SD)
63.9 (12.7)
Education (years), M (SD)
14.9 (2.7)
Alcohol (oz/wk), M (SD)2
1.4 (2.4)
Cigarettes per week, M (SD)2
6.7 (33.5)
Total cholesterol (mg/L), M (SD)
191.9 (37.9)
LDL-cholesterol (mg/L), M (SD)
115.4 (32.1)
HDL-cholesterol (mg/L), M (SD)
54.9 (15.7)
Triglycerides (mg/L), M (SD)2
108.9 (63.4)
Glucose (mg/L), M (SD)
92.3 (10.8)
2
Plasma homocysteine (μmol/L), M (SD)
9.9 (3.2)
Serum creatinine (μmol/L), M (SD)2
1.0 (0.2)
Systolic blood pressure (mmHg), M (SD)
128.3 (20.0)
Diastolic blood pressure (mmHg), M (SD)
76.8 (9.7)
Mean arterial pressure (mmHg), M (SD)
94.0 (11.9)
Body mass index (kg/m2), M (SD)
29.1 (6.0)
Waist circumference (cm), M (SD)
92.4 (15.1)
CES-D score, M (SD)2
7.5 (7.2)
Duration of diabetes (years), M (SD)
-

Diabetic
(n = 84)
65.3 (9.9)
13.6 (2.9)
0.8 (2.0)
9.0 (37.6)
165.5 (38.9)
92.4 (28.6)
44.9 (12.0)
146.9 (130.1)
131.5 (38.2)
11.2 (3.9)
1.2 (0.6)
135.3 (19.8)
78.3 (11.2)
97.3 (12.8)
32.6 (7.9)
103.6 (14.6)
9.7 (8.9)
10.6 (9.0)

Women, n (%)
302 (65.4)
37 (44.1)
African-American, n (%)
46 (10.0)
17 (20.2)
Depressed mood, n (%)
52 (11.4)
15 (17.9)
Drinker, n (%)
239 (51.7)
25 (29.8)
Smoker, n (%)
37 (8.0)
7 (8.3)
2
History of CVD, n (%)
51 (11.0)
18 (21.4)
Mild renal dysfunction, n (%)
126 (27.3)
27 (32.1)
Hypertensive, n (%)
265 (57.4)
73 (86.9)
Antihypertensive medications, n (%)
230 (49.8)
72 (85.7)
Cholesterol medications, n (%)
149 (32.3)
55 (65.5)
APOE-ε4 allele, n (%)
137 (29.7)
26 (31.0)
Note: t-tests were used for continuous variables; Fisher’s exact test was used for
categorical variables
1
2

unequal variances; Satterthwaite approximation used.
candidate variables for backward elimination procedure

M = mean; SD = standard deviation
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p
0.2871
<0.001
0.0151
0.562
<0.001
<0.001
<0.0011
0.0101
<0.0011
0.0071
0.0081
0.003
0.210
0.020
<0.0011
<0.001
0.0371
<0.001
0.014
0.105
<0.001
0.831
0.012
0.358
<0.001
<0.001
<0.001
0.797

hypertensive individuals were treated for hypertension at Wave 7 we could not use
treatment for hypertension as a covariate. Moreover, many investigators argue that it is
the observed blood pressure level, not the medicated blood pressure level, that is critical
in the destructive effects of blood pressure on cognitive function (Elias et al., 2004).
Controlled clinical trials have been mixed with regard to the improvement in cognitive
function with treatment for hypertension. Where treatment has affected cognitive
function, effects have been modest, if not trivial (Elias, Goodell, & Dore, 2012).
The remaining variables listed above were defined as candidate variables and
added to a model including the major predictors and covariates in the current study
(diabetes, PWV, age, education, gender, ethnicity, height, weight, heart rate, and MAP).
Stated differently, the basic model above was fixed in the regression model, and then a
backward elimination (α = 0.10) was performed using the candidate variables as defined
above.
Table 3.2 shows variables surviving the backward elimination (remaining
significant at p< .10) for each of the cognitive outcome variables. CES-D, alcohol
consumption, triglycerides, and CVD were each related to at least one cognitive outcome.
Therefore, these variables were added to the basic model to form the extended model.
Thus, the following two models were used for the following analyses: (1) the basic model
(age + education + gender + ethnicity + height + weight + heart rate + MAP), and (2) the
extended model (basic + CES-D + alcohol consumption + triglycerides + CVD).
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Table 3.2. Variables surviving backward elimination (p = 0.10) for each of the cognitive
outcome variables.
Cognitive Outcome
Predictor
b
SE
p
Global
CES-D
-0.017
0.004
<0.001
Verbal Memory
Alcohol consumption
0.030
0.016
0.070
VSOM
CES-D
-0.017
0.005
<0.001
Scanning & Tracking CES-D
-0.021
0.004
<0.001
Working Memory
Triglycerides
-0.0010
0.0005
0.046
Similarities
CES-D
-0.014
0.005
0.009
Executive Function
CES-D
-0.011
0.005
0.027
CVD
0.207
0.113
0.068
Full backward elimination model1:diabetes, PWV, age, education, gender, ethnicity,
height, weight, heart rate, MAP, alcohol consumption, triglycerides, CES-D, CVD, tHcy
1

The following variables were fixed in the backward elimination model: diabetes, PWV,
age, education, gender, ethnicity, height, weight, heart rate, and MAP were fixed in the
model.
Table 3.3. Regression coefficients (b) and standard errors (SE) for the diabetes × APOE
interaction.
Basic Model
Extended Model
Cognitive Outcome
b
SE
b
SE
Global
-0.489**
0.180
-0.437*
0.178
Verbal Memory
-0.482*
0.216
-0.470*
0.217
VSOM
-0.213
0.194
-0.174
0.194
Scanning & Tracking
-0.474**
0.182
-0.403*
0.178
Working Memory
-0.498*
0.225
-0.447*
0.226
Similarities
-0.600**
0.216
-0.562**
0.217
Executive Function
-0.353
0.211
-0.278
0.210
**p< 0.01; *p< 0.05
Basic model = age, education, sex, ethnicity, heart rate, height, weight, MAP
Extended model = age, education, sex, ethnicity, heart rate, height, weight, MAP, alcohol
consumption, triglycerides, CES-D, CVD
3.3. Diabetes × APOE Genotype Interaction
Table 3.3 shows regression coefficients for the diabetes × APOE genotype
interaction in relation to cognitive outcome measures. This interaction was significant
for all cognitive outcomes, with the exception of the Visual-Spatial Organization and
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Memory (VSOM) and Executive Function composites. This pattern of results was the
same with adjustment for the basic and extended models.
The nature of the diabetes × APOE interaction, with adjustment for the basic
model, is shown in Figure 3.1. Diabetic APOE-ε4 carriers performed lower than all other
groups on the Global (p< 0.01), Working Memory (p< 0.01), Verbal Memory (p< 0.05),
Scanning and Tracking (p< 0.01) composites and Similarities (p< 0.05). No other group
differences were observed for any cognitive outcome variables (all p> 0.23). The pattern
of results was the same with adjustment for the extended model.
Additionally, we examined the association between the diabetes × APOE
genotype interaction and the individual tests within the VSOM and EF composites. This
was done in order to determine if the diabetes × APOE interaction was associated with
any of the individual tests. For VSOM, the interaction effect was not related to any of the
individual tests (p range = 0.08-0.76). For EF, the interaction term was related to Trails
B (p= 0.005), but not COWA (p= 0.44).
3.4. PWV × Age Interaction
As can be seen in Table 3.4, the PWV × age interaction was significant for all
cognitive outcome measures, with the exception of the Working Memory composite.
This was true for the basic and extended models.
Table 3.5 illustrates the nature of the PWV × age interaction with results of
separate regression analyses by age tertile (<59 years, 59 – 69 years, and >69 years).
This approach represents the more classic method of probing interactions with continuous
variables, i.e. the association between PWV and cognitive function was examined within
age groups. For younger individuals, a generally positive association between PWV and
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Figure 3.1. Adjusted (least squares) means for cognitive outcome measures by diabetic status and APOE group for: (a) the Global
composite; (b) the Working Memory composite; (c) the Verbal Memory composite; (d) the Similarities subtest; and (e) the Scanning
and Tracking composite. Means are adjusted for age, education, gender, ethnicity, height, weight, heart rate, and MAP (basic model).
Cross-hatched bars, no APOE-ε4; white bars, APOE-ε4. Error bars represent standard error of the mean

Table 3.4. Regression coefficients (b) and standard errors (SE) for the PWV × age
interaction.
Basic Model
Extended Model
Cognitive Outcome
b
SE
b
SE
Global
-0.0037***
0.0010
-0.0035***
0.0010
Verbal Memory
-0.0037**
0.0012
-0.0036**
0.0012
VSOM
-0.0039***
0.0010
-0.0036***
0.0010
Scanning & Tracking
-0.0027**
0.0010
-0.0023*
0.0010
Working Memory
-0.0018
0.0012
-0.0018
0.0012
Similarities
-0.0028*
0.0012
-0.0026*
0.0012
Executive Function
-0.0038**
0.0011
-0.0035**
0.0011
Basic model = age, education, sex, ethnicity, heart rate, height, weight, MAP
Extended model = age, education, sex, ethnicity, heart rate, height, weight, MAP, alcohol
consumption, triglycerides, CES-D, CVD

cognitive outcome measures was observed. For the middle age tertile, PWV slopes were
close to zero. A negative association between PWV and cognitive outcomes was
observed for the oldest age tertile. Figures 3.2 – 3.4 show the relationship between PWV
and the Global composite for the <59, 59-69, and >69 age groups, respectively.
Figure 3.5 shows the nature of the interaction using the Johnson-Neyman
technique for the basic model. It will be recalled that this method, which estimates PWV
slopes and 95% confidence intervals for the Global composite for all ages within the
range of the data generated, provides PWV slopes for the full age range. It may be seen
that PWV was significantly and positively related to the Global composite for individuals
under 51 years of age, and was significantly and negatively related to the Global
composite for individuals above 71 years of age. These associations are also illustrated
in Figure 3.6, which shows predicted Global Composite z-scores by age and PWV. The
pattern of results was similar for other cognitive outcomes, and with adjustment for the
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Table 3.5. Regression coefficients (b) and standard errors (SE) expressing the association
between PWV and cognitive function by age tertiles (separate regression analyses done
for each age group).
Age Group
Cognitive Outcome
age< 591
Age 59 – 692
Age > 693
Global
b
0.046
-0.003
-0.043*
SE
0.038
0.027
0.019
Verbal Memory
b
0.089*
-0.005
-0.045*
SE
0.043
0.033
0.023
VSOM
b
0.071†
0.011
-0.045*
SE
0.040
0.028
0.022
Scanning &
b
-0.010
-0.011
-0.031
Tracking
SE
0.039
0.027
0.020
Working Memory
b
-0.014
-0.016
-0.023
SE
0.052
0.037
0.021
Similarities
b
0.073
0.007
-0.013
SE
0.048
0.031
0.024
Executive Function b
0.007
-0.013
-0.032
SE
0.048
0.032
0.021
†p< 0.10; *p< 0.05; **p< 0.01; ***p<0.001
1

n = 175
n = 176
3
n = 195
2

model: PWV, age, education, sex, ethnicity, heart rate, height, weight, MAP
NOTE: Similar [but non-significant] results are obtained for the younger individuals
when age<50 is used (n = 69)
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Figure 3.2. Relationship between PWV and Global Composite residuals for individuals
under 59 years of age. Adjusted for age, education, sex, ethnicity, heart rate, height,
weight, MAP
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Figure 3.3. Relationship between PWV and Global Composite residuals for individuals
59 – 69 years of age. Adjusted for age, education, sex, ethnicity, heart rate, height,
weight, MAP
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Figure 3.4. Relationship between PWV and Global Composite residuals for individuals
over 69 years of age. Adjusted for age, education, sex, ethnicity, heart rate, height,
weight, MAP
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Figure 3.5. PWV slopes and 95% confidence intervals by age estimated using the Johnson-Neyman technique for the Global
Composite (basic model).
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Figure 3.6. Association between PWV and the Global Composite, as modified by age.

extended model. Since positive relations between PWV and cognition were obtained
under the age of 51, other indices of arterial stiffness were examined to see if this same
pattern of results would be obtained.
In an additional analysis we examined the association between the PWV × age
interaction and the individual tests within the Working Memory composite, in order to
determine if the PWV × age interaction was associated with any of the individual tests
within this composite. The PWV × age interaction was related to Letter-Number
Sequencing (p= 0.03) and COWA (p= 0.02), but not Digit Span Forward (p= 0.76) or
Digit Span Backward (0.75).

3.5. Other Indices of Arterial Stiffness
Table 3.6 shows statistical main effects of the various measures of arterial
stiffness, including PWV, in relation to cognitive outcome measures. Other than PWV,
none of the other measures of arterial stiffness were related to the Global composite. The
only significant main effects observed were for AIx (Scanning and Tracking) and aPP
(VSOM).
Table 3.7 shows results for the arterial stiffness × age interaction. Similar to
results for the main effects, other than PWV, none of the arterial stiffness measures
interacted significantly with age. The only significant results were for bPP × age
(Working Memory and Executive Function), and aPP × age (Executive Function). Given
that none of the arterial stiffness measures satisfied the requirements for inclusion in
analyses (i.e. none were significantly related to the Global Composite), the analyses
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Table 3.6. Main effects - Regression coefficients (b) and standard errors (se) expressing the association between measures of arterial
stiffness and cognitive functioning
Arterial Stiffness Measure
Test
PWV
AIx
AP
bPP
aPP
Global
b
-0.029*
0.003
-0.003
-0.004
-0.005
se
0.014
0.004
0.006
0.003
0.003
Verbal Memory
b
-0.022
-0.000
-0.003
0.001
-0.002
se
0.017
0.005
0.007
0.004
0.004
Visual-Spatial Organization and Memory b
-0.021
0.002
-0.007
-0.004
-0.008*
se
0.015
0.004
0.006
0.003
0.003
Scanning and Tracking
b
-0.033*
0.008*
0.005
-0.006†
-0.002
se
0.014
0.004
0.006
0.003
0.003
Working Memory
b
-0.026
-0.002
-0.008
-0.004
-0.004
se
0.018
0.005
0.007
0.004
0.004
Similarities
b
-0.007
0.002
0.007
0.005
0.003
se
0.017
0.005
0.007
0.004
0.004
Executive Function
b
-0.033*
0.005
0.002
-0.003
-0.002
se
0.017
0.004
0.007
0.004
0.004
†p< 0.10; *p< 0.05
model = [arterial stiffness variable], age, education, sex, ethnicity, height, weight, heart rate, brachial MAP
PWV: pulse wave velocity
AIx: augmentation idex
AP: augmentation pressure
bPP: brachial pulse pressure
aPP: aortic pulse pressure
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Table 3.7. Arterial stiffness × age interactions - Regression coefficients (b) and standard errors (se) for the arterial stiffness × age
interaction.
Arterial Stiffness Measure
Test
PWV
AIx
AP
bPP
aPP
Global
b
-0.0037***
0.0001
-0.0003
-0.0003
-0.0003
se
0.0010
0.0002
0.0003
0.0002
0.0002
Verbal Memory
b
-0.0037**
0.0000
-0.0001
0.0000
-0.0001
se
0.0012
0.0003
0.0004
0.0002
0.0002
Visual-Spatial Organization and Memory b
-0.0039***
0.0002
-0.0000
-0.0002
-0.0001
se
0.0010
0.0003
0.0003
0.0002
0.0002
Scanning and Tracking
b
0.0027**
0.0000
-0.0005
-0.0003
-0.0003†
nh
se
0.0010
0.0002
0.0003
0.0002
0.0002
Working Memory
b
-0.0018
0.0001
-0.0003
-0.0003
-0.0005*
se
0.0012
0.0003
0.0004
0.0002
0.0002
Similarities
b
-0.0028*
-0.0001
-0.0002
-0.0002
-0.0002
se
0.0012
0.0003
0.0004
0.0002
0.0002
Executive Function
b
-0.0038**
-0.0001
-0.0006
-0.0005*
0.0005*
se
0.0011
0.0003
0.0003
0.0002
0.0002
†p< 0.10; *p< 0.05; **p< 0.01; ***p<0.001
model = [arterial stiffness variable], age, education, sex, ethnicity, height, weight, heart rate, brachial MAP
PWV: pulse wave velocity
AIx: augmentation index
AP: augmentation pressure
bPP: brachial pulse pressure
aPP: aortic pulse pressure

involving the full path model (discussed in the following section) include only PWV as a
measure of arterial stiffness.

3.6. Mediational Analyses
While path analysis does not establish causal associations between or among
variables, the term “effect” is used here to be consistent with its statistical use and the
vocabulary of path analysis.
Figure 3.7 shows individual component paths for the basic model with the Global
Composite as the outcome. From these component paths, the total conditional direct and
indirect effects may be calculated. The direct effect conditional on APOE genotype is
'
given by the following combination of the c 1 (diabetes → Global Composite) path and
'
the c 3 path (Diabetes × APOE → Global Composite) paths: conditional direct effect =

c '1 + c '3 [APOE genotype]. That is, the direct effect of diabetes is conditional on APOE

genotype. For example, for the APOE-ε4 carriers, the direct effect of diabetes would be
(within rounding error): -0.0558 + (-0.4975)(1) = -0.5533.
The conditional indirect effect is calculated in a similar fashion. However, the
indirect effect is conditional on both APOE genotype and age, and is given by: [ a1 +
a3 (APOE)][ b1 + b3 (age)]. As an example, the indirect effect of diabetes on the

Global Composite (through PWV) for a 73-year-old APOE-ε4 carrier is (within rounding
error): [1.3281 + 2.0285(1)][0.2798 + (-0.0041)(73)] = -0.0655.
The total effect would be the combination of the direct and indirect effects. For
the examples given above, the total effect would be: -0.5533 + (-0.0655) = -0.619.
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Figure 3.7. Simplified path model used to assess the conditional (moderated by age and APOE) indirect effect of diabetes on cognitive
function through PWV. Hayes (2012) model 22
Conditional indirect effect of diabetes on cognition through PWV = (a1 + a3[APOE]) (b1 + b3[age] )
Conditional direct effect of diabetes on cognition = c'1 + c'3[APOE]

Therefore, a 73-year-old diabetic APOE-ε4 carrier would be expected to perform 0.619
SD below the mean on the Global Composite.
Component paths relevant to the direct and indirect effects for other cognitive
outcomes are given for the basic model in Table 3.8 and for the extended model in Table
3.9. This information is given for the reader’s information; the direct and indirect effects
are calculated and provided in Tables 3.10-3.13 (discussed below).
Conditional direct effects (moderated by APOE genotype) and conditional
indirect effects (moderated by APOE genotype and age) for the basic model are given in
Tables 3.10 and 3.11. As can be seen in Table 3.10, none of the direct effects of diabetes
on cognitive function were statistically significant for the no-APOE-ε4 group.
Conversely, direct effects of diabetes on cognitive function for the APOE-ε4 group were
statistically significant for all cognitive outcome variables (Table 3.11)
This same pattern of results was observed with adjustment for the extended
covariate set (Tables 3.12 and 3.13). However, the direct effect of diabetes on VSOM no
longer remained statistically significant for the APOE-ε4 group. Effects remained for the
Global, Verbal Memory, Visual-Spatial Organization/Memory, Working Memory, and
Executive function composites, as well as for Similarities.
Conditional indirect effects of diabetes through PWV (effects moderated by age
as well as APOE) on cognitive function were positive for the younger individuals, and
negative for older individuals. This was true for both the basic (Tables 3.10 and 3.11)
and extended (Tables 3.12 and 3.13) models.
Although positive indirect effects between diabetes and cognitive function were
observed for the younger individuals, it is important to note that the net or total effect
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Table 3.8. Basic model component path coefficients (b) and standard errors (se) of the direct effects1 of diabetes on cognitive function
and conditional indirect effects2 of diabetes on cognitive function through PWV.
Direct Effect Component Path3
Indirect Effect Component Path4
Cognitive Outcome
c '1
c '3
a1
a3
b1
b3
Global
b
-0.0558
-0.4975**
1.3281***
2.0285**
0.2798***
-0.0041***
se
0.1043
0.1789
0.3734
0.6431
0.0717
0.0010
Verbal Memory
b
-0.0024
-0.4983*
1.3205***
2.0346**
0.2797**
-0.0041***
se
0.1262
0.2165
0.3730
0.6427
0.0868
0.0012
VSOM
b
-0.1145
-0.2290
1.3205***
2.0346**
0.2881***
-0.0042***
se
0.1132
0.1941
0.3730
0.6427
0.0778
0.0011
Scanning & Tracking b
0.0501
-0.4568*
1.3205***
2.0346**
0.1858*
-0.0029**
se
0.1063
0.1823
0.3730
0.6427
0.0731
0.0010
Working Memory
b
-0.0903
-0.4993*
1.3205***
2.0346**
0.1516
-0.0023
se
0.1326
0.2275
0.3730
0.6427
0.0912
0.0012
Similarities
b
0.0034
-0.6408**
1.3281***
2.0285**
0.2423**
-0.0033**
se
0.1270
0.2177
0.3734
0.6431
0.0873
0.0012
Executive Function
b
-0.1359
-0.3563
1.3205***
2.0346**
0.2807***
-0.0042***
se
0.1233
0.2115
0.3730
0.6427
0.0848
0.0011
***p< 0.001; **p< 0.01; *p<0.05
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP
Conditional indirect effect of diabetes on cognition through PWV = [a1 + a3(APOE)][b1 + b3(age)]
Conditional direct effect of diabetes on cognition = c'1 + c'3(APOE)
1

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV
3
direct effect component path: c'1 = diabetes → cognitive variable; c'3 = diabetes × APOE → cognitive variable
4
indirect effect component path: a1 = diabetes → PWV; a3 = diabetes × APOE → PWV; b1 = PWV → cognitive variable;
b1 = PWV × age → cognitive variable

2
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Table 3.9. Extended model component path coefficients (b) and standard errors (se) of the direct effects1 of diabetes on cognitive
function and conditional indirect effects2 of diabetes on cognitive function through PWV.
Direct Effect Component Path
Indirect Effect Component Path
'
'
Cognitive Outcome
c1
c3
a1
a3
b1
b3
Global
b
-0.0276
-0.4420*
1.1598**
2.1487***
0.2552***
-0.0038***
se
0.1040
0.1777
0.3633
0.6218
0.0714
0.0010
Verbal Memory
b
0.0188
-0.4812*
1.1487**
2.1542***
0.2684**
-0.0039***
se
0.1274
0.2179
0.3630
0.6216
0.0875
0.0012
VSOM
b
-0.0976
-0.1862
1.1487**
2.1542***
0.2627***
-0.0038***
se
0.1133
0.1938
0.3630
0.6216
0.0778
0.0011
Scanning & Tracking b
0.0729
-0.3796*
1.1487**
2.1542***
0.1504*
-0.0025*
se
0.1046
0.1789
0.3630
0.6216
0.0718
0.0010
Working Memory
b
-0.0552
-0.4509*
1.1487**
2.1542***
0.1471
-0.0022
se
0.1334
0.2282
0.3630
0.6216
0.0916
0.0012
Similarities
b
0.0211
-0.6041**
1.1598**
2.1487***
0.2240*
-0.0030*
se
0.1278
0.2184
0.3633
0.6218
0.0877
0.0012
Executive Function
b
-0.0985
-0.2822
1.1487**
2.1542***
0.2600**
-0.0039***
se
0.1226
0.2094
0.3630
0.6216
0.0829
0.0011
***p< 0.001; **p< 0.01; *p<0.05
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP, alcohol consumption, triglycerides, CES-D, CVD
Conditional indirect effect of diabetes on cognition through PWV = [a1 + a3(APOE)][b1 + b3(age)]
Conditional direct effect of diabetes on cognition = c'1 + c'3(APOE)
1
2

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV
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Table 3.10. Results for the no APOE-ε4 group, basic model. Path coefficients (b) and standard errors (se) representing conditional
direct effects1 of diabetes on cognitive function and conditional indirect effects2 of diabetes on cognitive function through PWV.
Conditional
Conditional Indirect Effect at Age Values
Direct Effect
Cognitive Outcome
49 years
55 years
64 years
73 years
80 years
Global
b
-0.056
0.104*
0.071*
0.022
-0.027
-0.066*
se
0.104
0.054
0.041
0.025
0.022
0.031
Verbal Memory
b
-0.002
0.107*
0.075*
0.027
-0.021
-0.059*
se
0.126
0.056
0.043
0.027
0.026
0.036
VSOM
b
-0.115
0.110*
0.077*
0.027
-0.023
-0.061*
se
0.113
0.060
0.046
0.029
0.024
0.032
Scanning & Tracking b
0.050
0.056
0.033
-0.002
-0.037*
-0.064*
se
0.106
0.042
0.033
0.024
0.021
0.027
Working Memory
b
-0.090
0.054
0.037
0.010
-0.017
-0.038
se
0.133
0.054
0.043
0.030
0.025
0.029
Similarities
b
0.003
0.108*
0.082*
0.043
0.004
-0.027
se
0.127
0.062
0.049
0.032
0.025
0.031
Executive Function
b
-0.136
0.101*
0.068*
0.018
-0.031
-0.070*
se
0.123
0.053
0.041
0.027
0.023
0.032
***p< 0.001; **p< 0.01; *p<0.05; †p<0.06
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP
1
2

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV
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Table 3.11. Results for the APOE-ε4 group, basic model. Path coefficients (b) and standard errors (se) representing direct effects1 of
diabetes on cognitive function and conditional indirect effects2 of diabetes on cognitive function through PWV
Conditional
Conditional Indirect Effect at Age Values
Direct Effect
Cognitive Outcome
49 years
55 years
64 years
73 years
80 years
Global
b
-0.553***
0.262*
0.179*
0.055
-0.069
-0.166*
se
0.158
0.114
0.090
0.060
0.052
0.067
Verbal Memory
b
-0.501**
0.272*
0.191*
0.068
-0.054
-0.149*
se
0.191
0.123
0.098
0.068
0.061
0.077
VSOM
b
-0.343*
0.279*
0.195*
0.069
-0.057
-0.155*
se
0.172
0.129
0.102
0.069
0.059
0.075
Scanning & Tracking b
-0.407*
0.142
0.084
-0.005
-0.093*
-0.162*
se
0.161
0.099
0.081
0.059
0.053
0.062
Working Memory
b
-0.590**
0.138
0.092
0.025
-0.043
-0.096
se
0.201
0.128
0.105
0.074
0.061
0.068
Similarities
b
-0.637***
0.274*
0.208*
0.109
0.009
-0.068
se
0.192
0.131
0.106
0.074
0.061
0.071
Executive Function
b
-0.492**
0.256*
0.172*
0.046
-0.080
-0.177*
se
0.187
0.115
0.092
0.064
0.056
0.068
***p< 0.001; **p< 0.01; *p<0.05; †p<0.06
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP
1
2

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV

(i.e.. the sum of the direct and indirect effect) of diabetes is either close to zero (as in the
no APOE-ε4 group) or negative (as in the APOE-ε4 group), consistent with analyses
discussed previously.

3.7. Secondary Analyses
A recent study (Schillaci et al., 2007) showed that a higher venticular contractility
rate is a main determinant of PWV in younger individuals. In the current data, ejection
duration, a measure of ventricular contractility rate, was modestly correlated with PWV
in the youngest (age < 59) and middle (59-69) age tertiles (r= -0.22 and -0.28,
respectively). Therefore, in secondary analyses, we additionally adjusted PWV for
ejection duration and the ejection duration × age interaction. The pattern of results with
these additional variables in the model was the same as that outlined above.
Previous research has also suggested that although PWV may be a useful measure
of arterial stiffness in older individuals, it may not be a reliable measure of arterial
stiffness in younger individuals, with AIx being the preferred measure for individuals
under 50 years of age (McEniery, Yasmin, Hall, et al., 2005). Therefore, we combined
PWV and AIx into a single arterial stiffness “composite” variable by standardizing each
measure and using standardized AIx for individuals under 50 years of age, and using
standardized PWV for individuals 50 and older. The resulting observed relationship
between the arterial stiffness composite, age, and the Global Composite is shown in
Figure 3.8. For older individuals, higher arterial stiffness was related to lower cognitive
function (p< 0.05). However, no association was observed for younger individuals (p>
0.05). When the arterial stiffness variable was used in the overall path model, indirect
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Table 3.12. Results for the no APOE-ε4 group, extended model. Path coefficients (b) and standard errors (se) representing direct
effects1 of diabetes on cognitive function and conditional indirect effects2 of diabetes on cognitive function through PWV.
Conditional
Conditional Indirect Effect at Age Values
Direct Effect
Cognitive Outcome
49 years
55 years
64 years
73 years
80 years
Global
b
-0.028
0.081*
0.054*
0.015
-0.025
-0.056*
se
0.104
0.049
0.036
0.022
0.020
0.030
Verbal Memory
b
0.019
0.087*
0.060*
0.019
-0.022
-0.054*
se
0.127
0.052
0.040
0.025
0.025
0.035
VSOM
b
-0.098
0.086*
0.059*
0.019
-0.020
-0.051*
se
0.113
0.054
0.041
0.026
0.021
0.029
Scanning & Tracking b
0.073
0.035
0.018
-0.008
-0.033
-0.053*
se
0.105
0.035
0.028
0.021
0.020
0.025
Working Memory
b
-0.055
0.047
0.032
0.009
-0.013
-0.031
se
0.133
0.049
0.040
0.028
0.023
0.027
Similarities
b
0.021
0.089*
0.068*
0.036
0.005
-0.020
se
0.128
0.056
0.044
0.029
0.022
0.028
Executive Function
b
-0.099
0.079*
0.053*
0.013
-0.027
-0.057*
se
0.123
0.046
0.035
0.022
0.022
0.031
***p< 0.001; **p< 0.01; *p<0.05; †p<0.06
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP, alcohol consumption, triglycerides, CES-D, CVD
1
2

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV
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Table 3.13. Results for the APOE-ε4 group, extended model. Path coefficients (b) and standard errors (se) representing direct effects1
of diabetes on cognitive function and conditional indirect effects2 of diabetes on cognitive function through PWV.
Conditional
Conditional Indirect Effect at Age Values
Direct Effect
Cognitive Outcome
49 years
55 years
64 years
73 years
80 years
Global
b
-0.470**
0.230*
0.155*
0.042
-0.071
-0.159*
se
0.158
0.109
0.087
0.060
0.052
0.064
Verbal Memory
b
-0.462*
0.249*
0.171*
0.054
-0.063
-0.154*
se
0.194
0.117
0.094
0.067
0.062
0.077
VSOM
b
-0.284
0.246*
0.170
0.056
-0.059
-0.148*
se
0.173
0.125
0.100
0.068
0.057
0.070
Scanning & Tracking b
-0.307*
0.099
0.051
-0.022
-0.095*
-0.152*
se
0.159
0.096
0.079
0.058
0.052
0.060
Working Memory
b
-0.506*
0.134
0.091
0.026
-0.039
-0.089
se
0.203
0.129
0.105
0.075
0.061
0.068
Similarities
b
-0.583**
0.253*
0.193*
0.104
0.014
-0.056
se
0.194
0.128
0.103
0.073
0.061
0.072
Executive Function
b
-0.381*
0.221*
0.147*
0.037
-0.074
-0.160*
se
0.185
0.106
0.085
0.060
0.053
0.065
***p< 0.001; **p< 0.01; *p<0.05
covariates = age, education, gender, ethnicity, heart rate, height, weight, MAP, alcohol consumption, triglycerides, CES-D, CVD
1
2

conditional on APOE; not mediated by PWV
conditional on APOE and age; mediated by PWV

57
Figure 3.8. Association between the arterial stiffness composite and the Global Composite, as modified by age.

effects from diabetes through PWV to cognition were observed for older individuals
only. All significant indirect effects were in a negative direction.

3.8. Summary of Results
Significant interactions were observed between diabetes and APOE such that the
diabetic APOE-ε4 carriers exhibited the lowest performance, compared with all other
groups. PWV × age interactions were also observed such that the most negative PWV
slopes in relation to cognitive performance were observed for the oldest individuals.
However, contrary to expectation, this trend was in the opposite direction for younger
individuals (under approximately 50 years of age).
For the overall path analysis, significant conditional direct associations between
diabetes and cognitive outcomes were observed for the APOE-ε4 carriers only.
Conditional indirect associations between diabetes and cognitive outcomes were
observed for younger (under ~50 years of age) and older (over ~70-80 years of age).
However these effects were in opposite directions, with a positive indirect effect in
younger individuals, and a negative indirect effect in younger individuals. These effects
were also larger in the APOE-ε4 carriers. Other indices of arterial stiffness, augmentation
index, augmentation pressure, brachial pulse pressure, and central pulse pressure, were
examined with respect to direct and indirect effects, but this examination did not clarify
relations between arterial stiffness and cognitive function because there were many fewer
significant indirect effects for these variables. While the complex indirect effects of
PWV are of theoretical interest, the magnitude of these effects was relatively small.
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4. DISCUSSION
4.1. Summary of Most Pertinent Findings
Previous studies have examined the association between type 2 diabetes and
cognitive function (Kodl & Seaquist, 2008); diabetes and PWV (Cameron & Cruikshank,
2007); and PWV and cognitive function (Elias et al., 2009; Waldstein et al., 2008). The
current study builds on this research and examines the associations between diabetes,
PWV, and cognitive function simultaneously. The major finding in the current study is
that PWV (a gold standard index of arterial stiffness) partially mediates the association
between diabetes and cognitive function. Although, as expected, direct associations
between diabetes and cognitive function were observed with indirect effects included in
the model. With respect to relative effect sizes, where these direct associations were
observed (i.e. in the APOE-ε4 group), they were approximately three times the magnitude
of the indirect effects. Additionally, this diabetes → PWV → cognitive function
association is modified by age and APOE genotype. In the following sections, we
elaborate on the specifics of these findings and discuss each of them. First, we will
discuss findings related to APOE genotype as an effect modifier of the relationship
between diabetes and cognitive function. Then, we turn to age as an effect modifier of
the relationship between PWV and cognitive function. Finally, we discuss how these
findings are inter-related in the context of a path model.
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4.2. Diabetes, APOE Genotype, and Cognitive Function
APOE was found to be an effect modifier of the association between diabetes and
cognitive function. In fact, deficits in cognitive performance were observed only for
those with diabetes and at least one APOE- ε4 allele. This finding is consistent with a
previous study using data from Wave 6 of the MSLS (Dore et al., 2009). Previous
investigations have also found APOE genotype to modify the associations of other
cardiovascular risk factors on cognitive function. APOE-ε4 has been shown to modify
the association of homocysteine with cognitive function (Elias et al., 2008); peripheral
vascular disease, carotid atherosclerosis, and diabetes with cognitive decline (Haan,
Shemanski, Jagust, et al., 1999); and diabetes with dementia (Irie, Fitzpatrick, Lopez, et
al., 2008; Peila, Rodriguez, & Launer, 2002).
There are several mechanisms that may explain this association. Hyperglycemia
in the cerebral vasculature is related to endothelial dysfunction (Messier & Gagnon,
2009). The APOE gene codes for the apoE protein, which is a cholesterol transport
protein produced mainly in the liver and brain (Mahley, 1988). ApoE plays an important
role not only in cholesterol transport, but also in amyloid-β (Aβ) clearance, neuronal
repair, and mediation of Aβ-related neurotoxicity (Bu, 2009). The apoE-ε4 isoform in
deficient in all of these areas, compared with apoE-ε2 and apoE-ε3 (Bu, 2009).
Additionally, the APOE-ε4 allele has been associated with increased cerebral amyloid
angiopathy (CAA; Thal et al., 2010), as well as increased white matter hyperintensities
and smaller brain volume in those with cerebrovascular disease (Decarli, Reed, Miller et
al., 1999). This enhanced Aβ deposition in the cerebral vasculature observed in APOE-ε4
carriers may interact synergystically with the increased vascular pathology (Puri,
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Kataoka, Uno, & Nicholls, 2012) and increased white matter hyperintensities (Novak et
al., 2006) observed in diabetic individuals, ultimately resulting in lower cognitive
function . Thus, diabetes is related to increased vascular pathology, and possession of
one or more APOE-ε4 alleles may either increase the degree of this pathology, or
exacerbate any effects of this pathology on cognitive performance.
Clinically, it may be important to treat diabetic APOE-ε4 carriers differently than
diabetic APOE-ε4 non-carriers. That is, diabetic APOE-ε4 carriers may need more
aggressive treatment with glucose lowering medications. CVD risk factors related to
diabetes, including PWV, may be important treatment targets to minimize cognitive
decrement in these individuals. Previous research has determined that treatment with
antidiabetic agents improves both cognitive function (Ryan et al., 2006) and endothelial
function (Mather, Verma, & Anderson, 2001). More recently, Lim et al. (2011) found
that treatment with a low-calorie liquid diet reversed pancreatic pathology in diabetic
individuals, resulting in normalized glucose values after one week. Although this
research needs to be replicated in larger samples, it would be interesting to see whether
this same protocol would improve arterial stiffness and cognitive performance. These
considerations may be especially important for older APOE-ε4 carriers.
We now turn to the next major association in the current study: the association
between PWV and cognitive function as modified by age.

4.3. PWV, Age, and Cognitive Function
An inverse association between PWV and cognitive function was observed in
older individuals. That is, the poorest performance was observed in the oldest individuals
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with the highest PWV. This is consistent with previous studies of PWV and cognitive
function (Elias et al., 2009) and longitudinal cognitive decline (Waldstein et al., 2008).
However, a positive association was observed between PWV and cognitive function for
younger individuals. This is an unexpected and novel finding and has not been addressed
in the literature.
There could be several reasons why this observation is unique to the current
study. First, studies of CVD risk factors, including PWV, have focused on older
individuals (e.g. Fujiwara et al., 2005; Benetos et al., 2012), most likely due to the fact
that arterial stiffness develops over time (Greenwald, 2007), and therefore is much more
common in older adults (Reference Values for Arterial Stiffness’ Collaboration, 2010;
Elias et al. 2011) and with increasing age beyond middle age. This emphasis on aging
arteries is very possibly why the association between PWV and cognitive function has
rarely been studied in younger individuals.
There are several possible explanations as to why PWV is positively related to
cognitive function in younger individuals. One possibility is that the positive association
between PWV and cognitive function for younger individuals may, like left ventricular
hypertrophy (Gaasch & Zile, 2011), represent an initially adaptive result of vascular
remodeling, which ultimately, but not initially, has adverse physiological consequences.
It is possible, however, that PWV is a reliable measure of arterial stiffness in
older, but not younger, individuals. Consistent with this explanation, Schillaci et al.
(2007) found PWV to be related to arterial stiffness in older individuals. However, in
younger individuals, PWV was related to the speed of ventricular contraction, rather than
arterial stiffness per se. The best index of ventricular contraction, although indirect,
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available in the current data is ejection duration. Using this measure, we examined
whether: 1) ejection duration is correlated with PWV in younger individuals, and 2) if
positive associations between PWV and cognitive function in younger individuals are
attenuated with adjustment for ejection duration. We found ejection duration to be
modestly correlated with PWV in younger individuals; however, with adjustment for
ejection duration, the pattern of results remained the same, i.e., PWV was related
positively to cognitive function in younger individuals. Consequently, the ventricular
contraction hypothesis as an explanation for the unexpected finding in younger subjects
was rejected.
Some previous research has also suggested AIx to be a better measure of arterial
stiffness in younger individuals, as compared with PWV (McEniery et al., 2005). When
we substituted AIx for PWV as the arterial stiffness measure in younger individuals only,
no association between arterial stiffness and cognitive function was observed. This is not
an unexpected finding because of the low prevalence of arterial stiffness below the age of
(Reference Values for Arterial Stiffness’ Collaboration, 2010; Elias et al. 2011).
However, it will be noted that AIx was also a poorer predictor of cognitive performance,
compared with PWV, in the older subjects in this study.
These analyses do not fully address reasons for the positive association between
PWV and cognitive function in younger individuals. Further study is needed examining
structural vascular correlates of PWV in younger individuals.
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4.4. From Diabetes to PWV to Cognitive Deficit
When the diabetes × APOE genotype and PWV × Age effects were combined in a
meditational path model, similar results to those outlined above were obtained. Direct
(non-mediated) associations between diabetes and cognitive function were observed for
APOE-ε4 carriers only. Diabetic APOE-ε4 carriers performed approximately half a
standard deviation below the mean on all cognitive measures. In addition to direct
effects, indirect effects (through PWV) were observed for all cognitive outcomes, with
the exception of the Working Memory composite.
In addition to being moderated by APOE genotype, these indirect effects were
also moderated by age. For younger individuals, positive indirect associations were
observed. As diabetes was consistently related positively to PWV, the sign of these
indirect associations was determined by the PWV × age interaction. Therefore, for
reasons discussed above, these positive associations should be interpreted with caution.
When AIx was used as the measure of arterial stiffness in these individuals, indirect
effects were observed for older individuals only. It should also be noted that even if
these positive indirect effects in younger individuals are valid, the overall associations
between diabetes and cognitive function variables were observed to be near zero (for the
no-APOE-ε4 group) or negative (for the APOE-ε4 group).
Conversely, negative indirect effects were observed for older individuals. In
these individuals, the associations between diabetes and cognitive function were partially
mediated by PWV. This was true for all cognitive measures, with the exception of
Working Memory and Similarities. This suggests that associations between diabetes and
cognitive function are in part mediated by arterial stiffness. All of these indirect
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associations were moderated by APOE genotype in addition to age. That is, all
associations were magnified in those with at least one APOE-ε4 allele.
The association between diabetes and increased arterial stiffness is wellestablished (see Stehouwer et al., 2008 for review). Increased atherosclerotic plaque
deposition, exacerbated by the increased inflammatory (i.e. immune) response
characteristic of the diabetic state is one mechanism which leads to increased arterial
stiffness. Chronic hyperglycemia results in the accelerated formation of advanced
glycation endproducts (AGEs), promoting the formation of oxidized low density
lipoproteins (LDL; Basta, Schmidt, & De Caterina, 2004), which is more atherogenic
than normal LDL (Xu, He, & King, 2005). In addition, increased oxidative stress
(increased production of reactive oxygen species), possibly due to increased AGE
formation (Stitt, Jenkins, & Cooper, 2002) or resulting directly from chronic
hyperglycemia (Brownlee, 2001), may decrease bioavailability of nitric oxide (a
vasodilator) and activate the protein kinase C pathway, resulting in maintenance of a
chronic inflammatory state (Jenkins, Hill, & Rowley, 2008). In addition to factors
leading to increased atherosclerotic plaque deposition, diabetes is also associated with
increased arterial calcification, further increasing arterial stiffness (Chen & Moe, 2003).
Higher levels of arterial stiffness, in turn, have been shown to relate to lowered
levels of cognitive function (M. F. Elias, Robbins, et al., 2009), and more accelerated
cognitive decline (Laurent, Cockroft, van Bortel,et al., 2006; Waldstein, Rice, Thayer,
Najjar, Scuteri, & Zonderman, 2008; Benetos, Watfa, Hanon, et al., 2012; Watson,
Sutton, Rosano, et al., 2011) in older, but not younger individuals. A recent study using
data from wave 7 of the MSLS (M. F. Elias, Robbins, et al., 2009) found that arterial
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stiffness, as indexed by PWV, interacted with age in relation to multiple cognitive
domains. The combination of older age and higher PWV was found to be associated with
the lowest level of cognitive performance, whereas lower age and PWV were associated
with better performance. Similarly, in the Baltimore Longitudinal Study of Aging,
Waldstein, Rice, Thayer, Najjar, Scuteri, & Zonderman (2008) found an interaction
between PWV and cognitive change, such that individuals with the highest PWV
exhibited the most pronounced rates of cognitive decline.

4.5. Cognitive Domains Associated with Diabetes
Although the specific cognitive tests used vary across studies, some
generalizations can be made concerning the cognitive abilities related to diabetes. The
most common finding is that diabetic subjects perform more poorly than nondiabetic
subjects on tests of attention, verbal and non-verbal memory, and processing speed (Kodl
& Seaquist, 2008; Roriz-Filho et al, 2009; van den Berg, Reijmer, & Biessels, 2009).
There is less agreement on other cognitive abilities, but some investigators have reported
that executive function (Kodl & Seaquist, 2008; Roriz-Filho et al, 2009), psychomotor
speed, and complex motor function (Kodl & Seaquist, 2008) are lowered in diabetic
individuals compared to non-diabetic individuals.
Consistent with these previous results, the current study suggests that diabetes is
related to decrements in performance on a broad, rather than specific, range of cognitive
abilities. Performance decrements in diabetic individuals were observed for all cognitive
measures, with the exception of the VSOM and EF composites. Similarly, indirect
associations (from diabetes to cognitive function through PWV) were observed for all
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variables, with the exception of Working Memory and Similarities. Given that arterial
stiffness involves arteries throughout the entire brain (Bornstein & Brown, 1991; Reitan
& Wolfson, 1993), this finding, commonly found in studies of hypertension and
cognition (Elias, Goodell, & Dore, 2012) is not unexpected.
The failure to see a relationship between the diabetes × APOE interaction term
and executive function may be due to the fact that Trails B, but not COWA was related to
the interaction term. Both Trails B and COWA are established indices of executive
function. It is not clear why we obtained negative findings for COWA, Possibly this is
related to the fact that our subjects are relatively highly educated and thus do well on
measures of verbal fluency. Trails B is significantly less dependent on verbal skills
(Rabbitt, 1998). It is possible that we would have found relationships between the
diabetes × APOE interaction and EF had we used even more sensitive measures of
executive function, which were not included in the MSLS test battery (e.g. the Stroop
Color-Word test). These are speculative explanations subject to further research.
The present study also points to APOE genotype as an important consideration in
studies of diabetes and cognitive functioning. In this study, decrements in cognitive
performance were observed only for those diabetic individuals with an APOE-ε4 allele.
Failure to consider this genetic variable may lead to under-estimation of the magnitude of
association between diabetes and cognitive abilities. APOE genotype plays a role in
repair of damaged neuronal structures; it has been argued that repair is slowed in persons
carrying the APOE-ε4 allele (Horsburgh, McCarron, White, & Nicoll, 2005). The
proportion of individuals with APOE-e4 genotype may differ among studies, particularly
where sample size is small.
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This may account for inconsistent findings in previous studies of diabetes and
cognitive function where data on APOE genotype are not available. While there is a
literature on other risk factors for cardiovascular disease and cognitive function, recent
literature searches indicate that there have been no studies in other laboratories that have
examined APOE in relation to diabetes.

4.6. Cognitive Domains Associated with PWV
We find that, like diabetes, PWV is associated with multiple cognitive domains.
The PWV × age interaction was significant for all cognitive composites, with the
exception of Working Memory. Data on the cognitive domains associated with PWV are
limited. One major reason for this is that many of the studies of PWV and cognitive
function use the MMSE or Modified MMSE as the sole measure of cognitive
performance (Zhong, 2011). Of the studies using multiple tests of cognitive function,
associations have been found between PWV and tests of: psychomotor and perceptual
speed (Watson et al., 2011) and executive function (Poels et al., 2007; Muller et al.,
2008). However, the results of these studies are made unclear by the fact that these
studies did not examine interactions between PWV and age. Of the previous studies from
other research groups, only one (Waldstein et al., 2008) included the PWV × age
interaction, in relation to cognitive decline. PWV was found to be related to decline in
verbal and nonverbal memory. Although far from being clear, the current literature
suggests that, like diabetes, PWV is related to multiple cognitive domains. Further study
using a variety of tests is necessary to determine specific cognitive domains related to
PWV.
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Although the APOE × age interaction term was not related to the Working
Memory composite, it seems clear that this interaction term was related to critical and
important indices of working memory. We speculate that that Digit Span Forward and
Digit Span Back were not related to the interaction term, as they are not difficult tasks for
highly performing individuals.

4.7. Limitations of the Current Study
The limitations of the current study should be noted. 1) The cross-sectional
nature of this study does not allow us to measure decline in cognitive function over time.
2) Given the cross-sectional design, duration of diabetes could not be measured
objectively, other than by self-report. Self-report of duration of diabetes is not a reliable
measure because it only provides information on the time of diagnosis of diabetes, not
when these disease processes first began. That is, an individual may be diabetic for a
period of time before this condition is diagnosed. 3) The sample size was too small to
allow examination of associations between diabetes and cognitive function in individuals
with one vs. two APOE-ε4 alleles. This limitation is generally true of most studies of
cardiovascular disease risk factors to date. 4) A1C, a recently emphasized index of
diabetes, was not available to confirm the diagnosis of diabetes. However, while an A1C
level greater than or equal to 6.5 has been adopted both nationally (American Diabetes
Association, 2012b) and internationally (World Health Organization, 2011) into
diagnostic criteria for diabetes, some debate still exists regarding the clinical utility of
this measure (Hare, Shaw, & Zimmet, 2012). 5) It was not possible to adjust for
antidiabetic medications in analyses with diabetes, as the majority of diabetic participants
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were taking antidiabetic (90.5%) medications. This high percentage of treatment is
related to the fact that once diabetes and hypertension are diagnosed in a longitudinal
study, it is not ethically permissible to deny diabetic or hypertensive patients treatment..
The MSLS study protocol requires all participants to be referred for treatment following a
wave of the study in which the likelihood of a disease process has been established. Due
to the increased awareness and aggressive treatment of diabetes, this is true of most
population-based longitudinal samples (Elias et al., 2004).

4.8. Strengths of the Current Study
The current study has several major strengths. First, it is the first to examine the
meditational role of PWV in the association between diabetes and cognitive function.
Second, it is one of the few studies to examine a wide range of ages thus leading to the
finding that PWV does not relate to cognition in the same way in younger and older
individuals. Third, many previous studies use patients with diagnosed diabetes and or
persons being treated for diabetes in clinics. The current sample used comprises
community-dwelling as compared to patients attending clinics and hospitals with a
diagnosis of diabetes. Therefore, the results may better generalize to the general
population. Fourth, the battery of cognitive tests is very likely the largest battery in use in
NIH-sponsored studies of cardiovascular disease and cognition. Further, the cognitive
measures were subject to factor analysis so that we were examining domains of
functioning as compared to individual specific abilities measured by individual clinical
tests. Sixth, the current study utilizes newer statistical methods (Hayes, 2012) to assess
interactions between continuous variables and mediation moderated by continuous
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variables. These methods have the advantage of not using arbitrary cutpoints to examine
the nature of such interactions, producing a clearer picture of the interaction across the
full range of both variables.

4.9. Summary
This study is the first to test a mediational model to test the hypothesis that PWV
is a mediator of the relationship between diabetes and cognitive performance. The
results indicated that PWV mediated the association between diabetes and cognitive
performance. This mediational relationship was modified such that the indirect effect of
diabetes through PWV was positive for younger individuals, and negative for older
individuals. Additionally, associations were magnified in APOE-ε4 carriers. It is
important to note that PWV did not fully mediate the diabetes-cognitive performance
relationship and that the indirect relationship between diabetes and cognitive function
was small compared with the direct relationship between diabetes and cognitive function.
Further study of other mediators is important.

4.10. Implications for Clinical Practice
The data have important implications with regard to populations of individuals
because of the prevalence of diabetes at all ages and the increasing prevalence of adult
onset diabetes with advancing age. Clinical trials will be necessary to determine the
reduction in cognitive decrement or impairment in relation to treatment for diabetes.
However, our data indicate that PWV plays a role in the relation between diabetes and
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cognition and that information on APOE genotype may be very important in the
neuropsychological diagnostic context.
Although no treatments for APOE genotype are available at present, several
treatment targets have been suggested for consideration in future studies. These include
pharmacological methods of converting apoE-ε4 to a molecule resembling apoE-ε3,
increasing apoE levels, and increasing apoE receptor expression (Bu, 2009). It will be
interesting to see in future clinical trials if these therapies will alleviate the cognitive
impairment seen in diabetic APOE-ε4 carriers.
At this time there are ethical considerations with respect to routinely assessing
APOE genotype as part of routine diagnostic examination and with respect to use of these
data once obtained (Roses, 1997). Whether APOE-ε4 genotype should be routinely
obtained on patients, even diabetic patients, is controversial given the social and
employment implications of revealing this information. Data on the importance of
APOE-ε4 to the diagnosis and treatment of dementia may play an important role in the
final resolution of this issue.
While the reporting of and APOE × diabetes interactions are important in terms of
population risk for lowered cognitive performance, the major finding of this study was
that PWV partially mediates between diabetes and cognitive performance. Higher levels
of PWV can be lowered by the same sets of drugs that lower hypertension and prevented
by the same set of lifestyle alterations that prevent hypertension.
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